Why Is Johnson & Johnson's Pharmaceutical Segment Outgrowing Its Other ... - Motley Fool

17-10-2013 Motley FoolComments (0)

Johnson & JohnsonPharmaceutical

3.1% year over year to $17.6 billion. However, a notable shift occurred -- its pharmaceutical segment outgrew its medical device and diagnostics segment in both sales growth and total revenue, now making it the largest of J&J's three business segments.

Read more on Motley Fool

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top